Matt Hewitt

Stock Analyst at Craig-Hallum

(2.62)
# 2,067
Out of 5,142 analysts
43
Total ratings
54.05%
Success rate
2.66%
Average return

Stocks Rated by Matt Hewitt

Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45$36
Current: $11.43
Upside: +214.96%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8$12
Current: $5.90
Upside: +103.39%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.98
Upside: +203.03%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30$32
Current: $22.91
Upside: +39.68%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45$64
Current: $39.56
Upside: +61.78%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135$140
Current: $183.13
Upside: -23.55%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25$10
Current: $0.27
Upside: +3,552.30%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35$30
Current: $11.22
Upside: +167.38%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $0.75
Upside: +830.48%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207$200
Current: $135.35
Upside: +47.77%
Initiates: Buy
Price Target: $10
Current: $1.71
Upside: +484.80%
Maintains: Hold
Price Target: $67$30
Current: $4.56
Upside: +557.89%
Initiates: Buy
Price Target: $400
Current: $0.24
Upside: +164,848.45%